Growing Cell Therapy Market Demand and Future Scope to 2030 – The Bollywood Ticket

The description

the global cell therapy market size was estimated at $8.1 billion in 2021 and should reach $23.9 billion by 2030, with a CAGR of 14.5% over the forecast period. The development of precision medicine and advancements in cell therapies in the context of their efficacy and manufacturing are expected to be the major market drivers. Additionally, development of stem cell banking facilities and resultant improvement in stem cell production, storage, and characterization are also expected to enhance market volumetric capabilities globally, which is expected to directly translate in revenue for this market at a larger level. Ongoing technological advancements in the parent and ancillary markets for the use of stem and non-stem cells are expected to bolster the demand over the forecast period. There are fewer cell therapy products marketed in the current market than there are research products. This is partly due to strict regulations and the high cost of stem cells.

Cell lines, such as induced pluripotent stem cells (iPSCs) and human embryonic stem cells (hESCs) are recognized as having high growth potential; as a result, many research entities and companies are investing heavily in R&D regarding products derived from iPSCs and hESCs.

The price of stem cell transplant varies from region to region. For example, the cost of transplantation in the United States is higher than in Germany or China. In March 2018, TiGenix’s Alofisel received marketing authorization in Europe. This is the first allogeneic stem cell therapy to be approved in Europe. In addition, revenues for certain products vary from country to country; for example, products like INVOSSA have received marketing clearance in Korea, but have not yet received marketing clearance in the United States. Growth is also influenced by the commercialization of revenue generation from unauthorized stem cell treatments.

Get a sample full PDF copy of the report:

Global cell therapy market definition

The therapy in which viable cells are injected, grafted or implanted into a patient to effect a medicinal effect is known as cell therapy; for example, in immunotherapy, T lymphocytes capable of fighting cancer cells via cell-mediated immunity are transplanted, and stem cells are grafted to regenerate diseased tissue.

Global cell therapy market dynamics

Drivers: Increase in the number of clinical studies for cell therapies

Cell therapies hold great therapeutic promise in various clinical applications. This has resulted in substantial global investments in research and their clinical application. Rapid advances in stem cell research have the potential to meet unmet demand from pharmaceutical entities, biotech entities, and physicians specializing in disease management. Several unknown therapies are in clinical development.

Additionally, government and private funding agencies are constantly offering grants to support projects at different stages of clinical trials, increasing the number of ongoing clinical trials.

Inquire before purchase @:

Constraints: Ethical Concerns

Human embryonic stem cell research is ethically controversial. The harvesting of embryonic stem cells involves the destruction of human embryos, which raises a moral concern. In addition, the strict regulations for obtaining intellectual property rights (IPR) for products or materials used in research are major constraints for the commercialization of these services. Ethical approval must be obtained to store cell lines and tissues in biorepositories to avoid the use of tissues for illegal purposes or to identify indirect diseases to claim insurance. Additionally, controversies surrounding the use of embryonic stem cells for research is hampering the market growth in several regions.

Scope of the Global Cell Therapy Market Research Report

The study categorizes the cell therapy market based on type of use and type of therapy at regional and global level.

By type of Outlook usage (Sales/Revenue, billion USD, 20172030)

By type of therapy (Sales/Revenue, billion USD, 20172030)

  • Allogeneic therapies
  • Autologous therapies

Outlook by region (Sales/Revenue, billion USD, 20172030)

  • North America (United States, Canada, Mexico)
  • South America (Brazil, Argentina, Colombia, Peru, Rest of Latin America)
  • Europe (Germany, Italy, France, United Kingdom, Spain, Poland, Russia, Slovenia, Slovakia, Hungary, Czech Republic, Belgium, Netherlands, Norway, Sweden, Denmark, Rest of Europe)
  • Asia Pacific (China, Japan, India, South Korea, Indonesia, Malaysia, Thailand, Vietnam, Myanmar, Cambodia, Philippines, Singapore, Australia and New Zealand, Rest of Asia Pacific)
  • The Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa, North Africa, Rest of MEA)

Research usage segment accounts for largest market share, by usage type

Cell therapy market analysis is based on the use of stem cells for clinical and research purposes. The research utilization segment dominated the market in the global cell therapy market and accounted for the largest revenue share of 58.3% in 2021. Currently, cell therapies (stem and non-stem cells) are mainly used for research projects, which in turn, led to a significant share of this segment’s revenue in 2021. Cell therapies are all opportunities for replacing, repairing, restoring and regenerating tissues, cells and organs damaged. As an alternative to traditional treatment strategies, researchers are investing heavily in the development of effective and safe cell treatments.

According to the CGT Catapult database of clinical trials, 59 cell and gene therapy trials are ongoing in the UK. Of all the therapeutic areas, oncology has the largest number of ongoing clinical trials. T lymphocytes, CD34+ and CD133+ stem cells, mesenchymal stem/stromal cells are cell types mainly used for clinical investigation. Neural cells, bone marrow mononuclear cells, fibroblasts, corneal cells, antigen-presenting cells, epithelial cells and chondrocytes are other cells explored for the development of cell therapies.

Asia Pacific represents the highest CAGR over the forecast period

On the basis of region, the global cell therapy market has been segmented into North America, AsiaPacific, Europe, South America, Middle East and Africa. In Asia-Pacific, the cell therapy market is expected to witness a lucrative growth rate of 15.5% during the forecast period. It is observed that the progress of stem cell therapy in Asian countries is better than that of the United States. This has enabled Asia to lead stem cell research. Several stem cell consortia in Asian countries aim to ensure coordinated and targeted R&D programs. Moreover, patients from Western countries are migrating to Asian countries for treatment, due to the flexible legal framework.

Companies from Japan, South Korea, India, China, Taiwan, Singapore and the rest of Asia actively participated in the conference. Furthermore, the large regional population and the untapped potential present in the region has resulted in the entry of global companies into the market. Additionally, this region offers relatively inexpensive manufacturing and operating units to conduct research. These factors are expected to play a major role in the expansion of the stem cell market in this region.

Report Description Request @

Main market players

Cell therapy market is slightly concentrated in nature with few global players operating in the market such as Kolon TissueGene, Inc., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., Castle Creek Biosciences, Inc. , MEDIPOST, Osiris Therapeutics, Inc., PHARMICELL Co., Ltd, Tameika Cell Technologies, Inc., Cells for Cells, NuVasive, Inc., Vericel Corporation and Celgene Corporation.

Comments are closed.